In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
In the latest session, Dynavax Technologies Corp (NASDAQ: DVAX) closed at $10.44 up 1.26% from its previous closing price of $10.31. In other words, the price has increased by $1.26 from its previous closing price. On the day, 2.71 million shares were traded. DVAX stock price reached its highest trading level at $10.49 during the session, while it also had its lowest trading level at $10.04.
Ratios:
For a deeper understanding of Dynavax Technologies Corp’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.82 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 21.56. For the most recent quarter (mrq), Quick Ratio is recorded 9.91 and its Current Ratio is at 10.80. In the meantime, Its Debt-to-Equity ratio is 0.43 whereas as Long-Term Debt/Eq ratio is at 0.42.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on February 11, 2025, Downgraded its rating to Sell and sets its target price to $12 from $15 previously.
On February 01, 2024, Goldman started tracking the stock assigning a Neutral rating and target price of $20.
On September 27, 2022, JMP Securities started tracking the stock assigning a Mkt Outperform rating and target price of $22.JMP Securities initiated its Mkt Outperform rating on September 27, 2022, with a $22 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Mar 24 ’25 when Novack David F sold 10,000 shares for $14.00 per share. The transaction valued at 140,000 led to the insider holds 8,078 shares of the business.
DAVID NOVACK bought 10,000 shares of DVAX for $140,000 on Mar 24 ’25. On Mar 18 ’25, another insider, Novack David F, who serves as the President & COO of the company, sold 14,020 shares for $13.58 each. As a result, the insider received 190,392 and left with 8,078 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DVAX now has a Market Capitalization of 1297274368 and an Enterprise Value of 835882432. As of this moment, Dynavax’s Price-to-Earnings (P/E) ratio for their current fiscal year is 59.76, and their Forward P/E ratio for the next fiscal year is 18.24. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.10. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.68 while its Price-to-Book (P/B) ratio in mrq is 2.19. Its current Enterprise Value per Revenue stands at 3.015 whereas that against EBITDA is 151.455.
Stock Price History:
The Beta on a monthly basis for DVAX is 1.32, which has changed by -0.112244904 over the last 52 weeks, in comparison to a change of 0.017286062 over the same period for the S&P500. Over the past 52 weeks, DVAX has reached a high of $14.63, while it has fallen to a 52-week low of $9.74. The 50-Day Moving Average of the stock is -19.87%, while the 200-Day Moving Average is calculated to be -13.54%.
Shares Statistics:
For the past three months, DVAX has traded an average of 2.45M shares per day and 3509130 over the past ten days. A total of 125.45M shares are outstanding, with a floating share count of 118.47M. Insiders hold about 4.66% of the company’s shares, while institutions hold 101.65% stake in the company. Shares short for DVAX as of 1743379200 were 18397661 with a Short Ratio of 7.50, compared to 1740700800 on 18935730. Therefore, it implies a Short% of Shares Outstanding of 18397661 and a Short% of Float of 18.35.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The stock of Dynavax Technologies Corp (DVAX) is currently being evaluated by 3.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is $0.09, with high estimates of $0.09 and low estimates of $0.08.
Analysts are recommending an EPS of between $0.36 and $0.28 for the fiscal current year, implying an average EPS of $0.33. EPS for the following year is $0.53, with 3.0 analysts recommending between $0.68 and $0.38.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $69.39M this quarter.It ranges from a high estimate of $76M to a low estimate of $63.47M. As of the current estimate, Dynavax Technologies Corp’s year-ago sales were $50.79MFor the next quarter, 5 analysts are estimating revenue of $84.15M. There is a high estimate of $89M for the next quarter, whereas the lowest estimate is $81M.
A total of 5 analysts have provided revenue estimates for DVAX’s current fiscal year. The highest revenue estimate was $340M, while the lowest revenue estimate was $316.37M, resulting in an average revenue estimate of $326.35M. In the same quarter a year ago, actual revenue was $277.25MBased on 5 analysts’ estimates, the company’s revenue will be $386.2M in the next fiscal year. The high estimate is $410M and the low estimate is $348.09M.
